---
layout: default
title: Tenofovir Alafenamide
description: "Tenofovir Alafenamide çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 3 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 164
evidence_level: L5
indication_count: 3
---

# Tenofovir Alafenamide

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>3</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Tenofovir Alafenamide è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Tenofovir Alafenamide å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Tenofovir alafenamideï¼ˆéŸ‹ç«‹å¾—ï¼‰æ˜¯æ ¸è‹·é…¸åè½‰éŒ„é…¶æŠ‘åˆ¶åŠ‘ï¼Œé™¤ç¾æœ‰ HIV/HBV é©æ‡‰ç—‡å¤–ï¼ŒTxGNN é æ¸¬å…¶å° SIV æ„ŸæŸ“å…·æ½›åŠ›ï¼Œå·²æœ‰è‡¨åºŠè©¦é©—åŠæ–‡ç»æ”¯æŒã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Tenofovir alafenamide (TAF) |
| DrugBank ID | DB09299 |
| å°ç£å•†å“å | éŸ‹ç«‹å¾—è†œè¡£éŒ ã€é”å¯æ®è†œè¡£éŒ ã€å¿…å…‹é”è†œè¡£éŒ ç­‰ |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | HIV-1 æ„ŸæŸ“æ²»ç™‚ã€HIV æš´éœ²å‰é é˜² (PrEP)ã€æ…¢æ€§ B å‹è‚ç‚ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | SIV æ„ŸæŸ“ã€è²“æ„›æ»‹ç—…ã€ç¥ç¶“ç™¼è‚²éšœç¤™ |
| æœ€é«˜è­‰æ“šç­‰ç´š | **L2**ï¼ˆå–®ä¸€ RCT / å¤šå€‹ Phase 2ï¼‰ |
| TxGNN åˆ†æ•¸ | 0.875ï¼ˆSIV æ„ŸæŸ“ï¼‰ |

## ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†

### ä½œç”¨æ©Ÿè½‰æ”¯æŒ

Tenofovir alafenamide æ˜¯ tenofovir çš„å‰é©…è—¥ç‰©ï¼Œé€éæŠ‘åˆ¶åè½‰éŒ„é…¶é˜»æ–·ç—…æ¯’è¤‡è£½ã€‚å…¶æ©Ÿè½‰å°æ‰€æœ‰ä¾è³´åè½‰éŒ„é…¶çš„é€†è½‰éŒ„ç—…æ¯’ï¼ˆåŒ…æ‹¬ HIVã€SIVã€FIVï¼‰ç†è«–ä¸Šå‡æœ‰æ•ˆã€‚

### é æ¸¬é©æ‡‰ç—‡åˆ†æ

1. **SIV æ„ŸæŸ“**ï¼ˆçŒ´å…ç–«ç¼ºä¹ç—…æ¯’ï¼‰
   - TxGNN åˆ†æ•¸ï¼š0.875ï¼ˆæ’åç¬¬ 1ï¼‰
   - SIV èˆ‡ HIV é«˜åº¦åŒæºï¼Œå¸¸ä½œç‚º HIV ç–«è‹—èˆ‡æ²»ç™‚ç ”ç©¶æ¨¡å‹
   - æ©Ÿè½‰é«˜åº¦ç›¸é—œï¼šåŒç‚ºé€†è½‰éŒ„ç—…æ¯’

2. **è²“æ„›æ»‹ç—…ï¼ˆFIV æ„ŸæŸ“ï¼‰**
   - TxGNN åˆ†æ•¸ï¼š0.813
   - FIV äº¦ç‚ºé€†è½‰éŒ„ç—…æ¯’ï¼Œæ©Ÿè½‰ç›¸ä¼¼

3. **ç¥ç¶“ç™¼è‚²éšœç¤™**
   - TxGNN åˆ†æ•¸ï¼š0.752
   - è­‰æ“šè¼ƒå¼±ï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶

## è‡¨åºŠè©¦é©—è­‰æ“š

### SIV æ„ŸæŸ“ç›¸é—œè©¦é©—

| NCT ç·¨è™Ÿ | è©¦é©—åç¨± | éšæ®µ | ç‹€æ…‹ |
|----------|----------|------|------|
| NCT02738385 | Tenofovir alafenamide ç”¨æ–¼ SIV/SHIV æ„ŸæŸ“æ†æ²³çŒ´ä¹‹ PK ç ”ç©¶ | Phase 1 | å·²å®Œæˆ |

**è©¦é©—æ‘˜è¦**ï¼šè©²è©¦é©—è©•ä¼° TAF åœ¨ SIV/SHIV æ„ŸæŸ“æ†æ²³çŒ´æ¨¡å‹ä¸­çš„è—¥ç‰©å‹•åŠ›å­¸ç‰¹æ€§ï¼Œç‚ºå°‡ TAF æ‡‰ç”¨æ–¼éäººéˆé•·é¡æ„ŸæŸ“æ¨¡å‹æä¾›åŸºç¤æ•¸æ“šã€‚

## æ–‡ç»è­‰æ“š

### SIV æ„ŸæŸ“ç›¸é—œæ–‡ç»ï¼ˆå…± 9 ç¯‡ï¼‰

| PMID | æ¨™é¡Œæ‘˜è¦ | å¹´ä»½ |
|------|----------|------|
| 35426679 | é•·æ•ˆ TAF å¥ˆç±³è£½åŠ‘åœ¨æ†æ²³çŒ´çš„è—¥ç†å­¸è©•ä¼° | 2022 |
| 33958620 | é•·æ•ˆ TAF æ³¨å°„åŠ‘åœ¨çŒ´æ¨¡å‹çš„é é˜²æ•ˆæœ | 2021 |
| 32908166 | é•·æ•ˆ Cabotegravir + TAF çµ„åˆåœ¨ SHIV æ„ŸæŸ“æ¨¡å‹çš„è©•ä¼° | 2020 |
| 32561755 | TAF é•·æ•ˆè£½åŠ‘åœ¨ SIV çŒ´æ¨¡å‹çš„åˆ†å¸ƒç ”ç©¶ | 2020 |
| 30992367 | é•·æ•ˆ Tenofovir å‰é©…è—¥åœ¨æ†æ²³çŒ´çš„è—¥å‹•å­¸ | 2019 |

### è­‰æ“šå¼·åº¦è©•ä¼°

- è‡¨åºŠè©¦é©—ï¼š1 é … Phase 1ï¼ˆæ†æ²³çŒ´ PK ç ”ç©¶ï¼‰
- PubMed æ–‡ç»ï¼š9 ç¯‡ï¼Œä¸»è¦ç‚ºå‹•ç‰©æ¨¡å‹ç ”ç©¶
- **ç¶œåˆè­‰æ“šç­‰ç´šï¼šL2**ï¼ˆæœ‰è‡¨åºŠè©¦é©—éšæ®µç ”ç©¶ï¼Œå¤šç¯‡å‰è‡¨åºŠæ–‡ç»ï¼‰

## å°ç£ä¸Šå¸‚è³‡è¨Š

### å·²æ ¸å‡†ç”¢å“ï¼ˆå…± 13 é …ï¼‰

| è¨±å¯è­‰è™Ÿ | å•†å“å | æˆåˆ†çµ„åˆ | é©æ‡‰ç—‡ |
|----------|--------|----------|--------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027163è™Ÿ | éŸ‹ç«‹å¾—è†œè¡£éŒ  25 æ¯«å…‹ | TAF å–®æ–¹ | æ…¢æ€§ B å‹è‚ç‚ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027012è™Ÿ | é”å¯æ®è†œè¡£éŒ  | Emtricitabine + TAF | HIV PrEP |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027398è™Ÿ | å¿…å…‹é”è†œè¡£éŒ  | Bictegravir + Emtricitabine + TAF | HIV æ²»ç™‚ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027464è™Ÿ | èˆ’ç™¼æ³°è†œè¡£éŒ  | Emtricitabine + TAF | HIV æ²»ç™‚ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027645è™Ÿ | æ¬£ä»–ä½³è†œè¡£éŒ  | Darunavir + Cobicistat + Emtricitabine + TAF | HIV æ²»ç™‚ |

### å¥ä¿çµ¦ä»˜ç‹€æ…‹

ä¸»è¦è¤‡æ–¹ç”¢å“å‡æœ‰å¥ä¿çµ¦ä»˜ï¼Œå–®æ–¹éŸ‹ç«‹å¾—ç”¨æ–¼ B è‚æ²»ç™‚äº¦æœ‰çµ¦ä»˜ã€‚

## å®‰å…¨æ€§è€ƒé‡

### è—¥ç‰©äº¤äº’ä½œç”¨

| äº¤äº’ä½œç”¨è—¥ç‰© | åš´é‡ç¨‹åº¦ | èªªæ˜ |
|--------------|----------|------|
| TAS2R39 ç›¸é—œè—¥ç‰© | è¼•åº¦ | è‹¦å‘³å—é«”äº¤äº’ä½œç”¨ï¼Œè‡¨åºŠæ„ç¾©ä¸æ˜ |

### ä¸»è¦ä¸è‰¯åæ‡‰

- è…åŠŸèƒ½å½±éŸ¿ï¼ˆè¼ƒèˆŠå‹ TDF æ”¹å–„ï¼‰
- éª¨å¯†åº¦ä¸‹é™ï¼ˆè¼ƒèˆŠå‹ TDF æ”¹å–„ï¼‰
- é ­ç—›ã€å™å¿ƒã€è…¹ç€‰

### ç‰¹æ®Šæ—ç¾¤æ³¨æ„äº‹é …

- è…åŠŸèƒ½ä¸å…¨ï¼šeGFR < 15 éœ€è¬¹æ…
- æ‡·å­•ï¼šCategory Bï¼Œæ¬Šè¡¡åˆ©å¼Š


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Bone Diseases** ğŸŸ¡ Moderate
- In clinical trials, tenofovir disoproxil fumarate (DF) was associated with slightly greater reductions in bone mineral density (BMD) and increases in biochemical markers of bone metabolism, suggesting increased bone turnover relative to comparators. ...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- Tenofovir alafenamide (as a single ingredient product) is not recommended in patients with decompensated liver dysfunction (Child-Pugh B or C); safety and efficacy have not been established in these patients.  No dose adjustment of tenofovir alafenam...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- Tenofovir is primarily eliminated by the kidneys via glomerular filtration and active tubular secretion.  Serum creatinine, estimated CrCl, urine glucose, and urine protein should be assessed in all patients before/when starting tenofovir (alafenamid...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- Tenofovir alafenamide (as a single ingredient product) is not recommended in patients with decompensated liver dysfunction (Child-Pugh B or C); safety and efficacy have not been established in these patients.  No dose adjustment of tenofovir alafenam...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- Tenofovir is primarily eliminated by the kidneys via glomerular filtration and active tubular secretion.  Serum creatinine, estimated CrCl, urine glucose, and urine protein should be assessed in all patients before/when starting tenofovir (alafenamid...

*å¦æœ‰ 2 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬å¯ä¿¡åº¦è©•ä¼°

| é æ¸¬é©æ‡‰ç—‡ | è­‰æ“šç­‰ç´š | å¯ä¿¡åº¦ | å»ºè­° |
|------------|----------|--------|------|
| SIV æ„ŸæŸ“ | L2 | é«˜ | ä¸»è¦ä½œç‚ºç ”ç©¶æ¨¡å‹ï¼Œéäººé¡æ²»ç™‚ç”¨é€” |
| è²“æ„›æ»‹ç—… | L4 | ä¸­ | ç¸é†«é ˜åŸŸå¯é€²ä¸€æ­¥ç ”ç©¶ |
| ç¥ç¶“ç™¼è‚²éšœç¤™ | L5 | ä½ | æ©Ÿè½‰é—œè¯ä¸æ˜ç¢º |

### è‡¨åºŠæ‡‰ç”¨å»ºè­°

1. **SIV æ„ŸæŸ“**ï¼šå·²æœ‰å……åˆ†å‹•ç‰©æ¨¡å‹æ•¸æ“šï¼Œé©åˆä½œç‚º HIV ç ”ç©¶çš„è½‰è­¯å¹³å°
2. **è²“æ„›æ»‹ç—…**ï¼šå¯è€ƒæ…®ç¸é†«è‡¨åºŠè©¦é©—
3. **ç¥ç¶“ç™¼è‚²éšœç¤™**ï¼šç›®å‰è­‰æ“šä¸è¶³ï¼Œä¸å»ºè­°è‡¨åºŠæ‡‰ç”¨

### å¾ŒçºŒç ”ç©¶æ–¹å‘

- é•·æ•ˆ TAF è£½åŠ‘åœ¨ HIV PrEP çš„è‡¨åºŠæ‡‰ç”¨
- ç¸é†«é ˜åŸŸ FIV æ²»ç™‚çš„å¯è¡Œæ€§è©•ä¼°

---

*æœ¬ç­†è¨˜ç”± TxGNN é æ¸¬ç³»çµ±ç”¢ç”Ÿï¼Œåƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚*
*æ›´æ–°æ—¥æœŸï¼š2026-02-11*


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Avelumab]({{ "/drugs/avelumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cobicistat]({{ "/drugs/cobicistat/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Polyethylene Glycol 400]({{ "/drugs/polyethylene_glycol_400/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Oxybutynin]({{ "/drugs/oxybutynin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Caspofungin]({{ "/drugs/caspofungin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Tenofovir Alafenamideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/tenofovir_alafenamide/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_tenofovir_alafenamide,
  title = {Tenofovir Alafenamideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/tenofovir_alafenamide/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
